Telmisartan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PHARMAC (New Zealand) and TLV (Sweden) recommended or restricted telmisartan, while AWMSG (Wales) did not recommend it.
Assessment has run over 11.2 years, from 24 May 2006 at PHARMAC (New Zealand) to 19 Jul 2017 at HAS (France).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for telmisartan, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2017; on this evidence the file is dormant.
PHARMAC (New Zealand) was first to assess telmisartan, on 24 May 2006; SMC (Scotland) did not open a file until 9 May 2010 — a wide spread of 4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
HAS (France) is the only agency to have returned to telmisartan, recording 4 separate entries.
Coverage is narrow: only 5 of the 18 agencies here have assessed telmisartan.
The full ledger for telmisartan reads 3 recommended, 2 other, 1 non-submission and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 19 Jul 2017 | Listing renewal (Transparency Committee) | SMR substantial | source |
| SMC (Scotland) | 9 May 2010 | For use in cardiovascular prevention or type 2 diabetes mellitus | not recommended | source |
| AWMSG (Wales) | 24 Feb 2010 | For cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with manifest atherothrom… | not endorsed (non-submission) | source |
| TLV (Sweden) | 15 Feb 2008 | Micardis får begränsad subvention | restricted subsidy | source |
| PHARMAC (New Zealand) | 24 May 2006 | Hypertension | PTAC advice: Cost Neutral · decision reached | source |
3 further decisions for telmisartan, across 1 agency, are not shown here. They link to 1 further source document.
Related molecules
- valsartan — same ATC class C09C — Renin-angiotensin system
- candesartan — same ATC class C09C — Renin-angiotensin system
- sacubitril / valsartan — same ATC class C09C — Renin-angiotensin system
- losartan — same ATC class C09C — Renin-angiotensin system
- olmesartan — same ATC class C09C — Renin-angiotensin system
- omalizumab — also decided by HAS in 2017Q3
Coverage: 8 decisions for telmisartan from 5 agencies, 2006 to 2017. Data to 7 Sep 2026. ATC class C09C — Renin-angiotensin system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.